WallStreetZenWallStreetZen

NASDAQ: AARD
Aardvark Therapeutics Inc Stock Ownership - Who owns Aardvark Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Aardvark Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Nelson SunCFO;COO2026-09-1162,000$5.18
$321.16kSell
Nelson SunCFO;COO2026-09-1014,754$5.00
$73.78kSell
Tienli LeeChief Executive Officer2025-12-117,000$14.49
$101.40kBuy
Nelson SunChief Financial Officer2025-12-113,000$14.40
$43.20kBuy
Bryan JonesChief Operating Officer2025-10-151,250$4.24
$5.30kBuy
Tienli LeeChief Executive Officer2025-10-151,229$4.24
$5.21kBuy

1 of 1

AARD insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when AARD insiders and whales buy or sell their stock.

AARD Shareholders

What type of owners hold Aardvark Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Decheng Capital Global Life Sciences Fund IV LP17.90%3,917,299$19.66MInsider
Tienli Lee13.83%3,025,641$15.19MInsider
Vickers Venture Fund VI Pte Ltd9.37%2,050,902$10.30MInsider
Cormorant Asset Management LP4.51%987,689$4.96MInsider
Jeffrey Chi0.61%133,364$669.49kInsider
Nelson Sun0.16%35,475$178.08kInsider
Dechen0.02%3,917$19.66kInstitution
Decheng Capital LLC0.02%3,917$19.66kInstitution
Citadel Advisors LLC0.01%1,283$6.44kInstitution
Citade0.01%1,283$6.44kInstitution

1 of 3

AARD vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
AARD0.04%46.39%Net SellingNet Selling
BDTX0.06%35.18%Net BuyingNet Buying
MIST0.04%10.86%Net Selling
VANI0.00%100.00%Net BuyingNet Buying
CBUS0.02%64.61%Net Buying
View Top Biotech Stocks

Aardvark Therapeutics Stock Ownership FAQ

Who owns Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ: AARD) is owned by 0.04% institutional shareholders, 46.39% Aardvark Therapeutics insiders, and 53.57% retail investors. Decheng Capital Global Life Sciences Fund IV LP is the largest individual Aardvark Therapeutics shareholder, owning 3.92M shares representing 17.90% of the company. Decheng Capital Global Life Sciences Fund IV LP's Aardvark Therapeutics shares are currently valued at $20.17M.

If you're new to stock investing, here's how to buy Aardvark Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.